JBC Advanced Peptides, Inc.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roig, J.
Right arrow Articles by Traugh, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roig, J.
Right arrow Articles by Traugh, J. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 44, 31119-31122, October 29, 1999

COMMUNICATION
p21-activated Protein Kinase gamma -PAK Is Activated by Ionizing Radiation and Other DNA-damaging Agents
SIMILARITIES AND DIFFERENCES TO alpha -PAK*

Joan Roig and Jolinda A. TraughDagger

From the Department of Biochemistry, University of California, Riverside, California 92521

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The p21-activated protein kinase gamma -PAK is activated 2-5-fold in response to ionizing radiation (IR) in 3T3-L1 fibroblasts and U937 leukemia cells. gamma -PAK is activated in a dose- and time-dependent manner. Doses from 1 to 100 Gy result in significant stimulation of activity at 30 min, whereas maximal stimulation is observed at 120 min after irradiation. UV (80 J/m2) and the DNA-damaging drugs cytosine beta -D-arabinofuranoside (AraC) and cis-platinum(II)diammine dichloride (cisplatin) also induce gamma -PAK activation. The activation of gamma -PAK in response to IR or AraC is dependent on tyrosine kinase and phosphoinositide 3-kinase activity, as demonstrated by use of the inhibitors genistein and wortmannin; in contrast activation of gamma -PAK by cisplatin and UV is not affected significantly by these inhibitors, suggesting that gamma -PAK can be activated by more than one pathway in response to different types of DNA damage. In contrast to gamma -PAK, alpha -PAK and JNK are activated only by cisplatin and UV in 3T3-L1 cells, suggesting differential regulation of the protein kinases. This is the first time that members of the Ste20/PAK family of protein kinases have been shown to be involved in the cellular response to IR and other DNA-damaging agents.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The p21-activated protein kinases (PAK)1 are activated by the small G-proteins Rac 1 and Cdc42 (1-3). Three mammalian PAKs are known: alpha -PAK (PAK1, 68 kDa), beta -PAK (PAK3, 65 kDa), and gamma -PAK (PAK2, PAK I, 58-60 kDa). gamma -PAK is unique among the mammalian members of the PAK family, as it is activated by caspase cleavage during apoptosis and can induce some of the changes involved in this death program (4-6). gamma -PAK appears to have cytostatic properties, as injection of the active enzyme into frog embryos results in cleavage arrest at mitotic metaphase (7). gamma -PAK is activated in response to cell stress (8) and serum starvation,2 in contrast to the related alpha -PAK, which appears to be involved in the control of the cytoskeletal architecture (9-11) and is activated by growth factors (12) and insulin (13). When 3T3-L1 cells are subjected to hyperosmotic stress, gamma -PAK is activated by a two-step mechanism involving translocation to the particulate fraction and activation of the protein kinase in a phosphoinositide 3-kinase (PI3-kinase)-dependent manner (8). gamma -PAK involvement in cell cycle regulation is supported by data showing that the protein kinase phosphorylates and regulates Raf-1 (14).

DNA damage is a major threat to cells; failure to repair the DNA before cell division causes genomic instability or lethality and a predisposition to cancer in multicellular organisms. Agents that induce DNA damage such as ionizing radiation (IR), ultraviolet light (UV), or chemotherapeutic drugs such as cis-platinum(II)diammine dichloride (cisplatin) or cytosine beta -D-arabinofuranoside (AraC) lead to activation of the DNA repair machinery of the cell and of different signaling pathways that transiently inhibit the cell cycle. This cytostatic response allows DNA repair prior to cell division (15-18).

In this study, IR and other DNA-damaging agents have been used to examine whether gamma -PAK could be involved in the cytostatic response to DNA damage. It is shown that gamma -PAK is activated in response to IR in a dose- and time-dependent manner. UV and the DNA-damaging drugs cisplatin and AraC also activate gamma -PAK, suggesting that different types of DNA damage trigger the activation of the protein kinase. The possible relationship between the observed gamma -PAK activation and its described cytostatic properties is discussed.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Cell culture media and reagents were purchased from Life Technologies, Inc. Okadaic acid was from LC Laboratories. Histone 4, leupeptin, pepstatin, and aprotinin were from Roche Molecular Biochemicals. Wortmannin, AraC, cisplatin, and myelin basic protein were from Sigma. Genistein was from Alexis Co. Ly 294002 was from Calbiochem. RR-1 anti-PAK antibody was obtained as described previously (7). Antibodies against gamma -PAK (N19, C20) and alpha -PAK (N20), peroxidase-coupled secondary antibodies, and protein G-agarose were purchased from Santa Cruz Biotechnology. The enhanced chemiluminescent (ECL) detection kit was from Amersham Pharmacia Biotech. [gamma -32P]ATP was purchased from NEN Life Science Products. All other chemicals were obtained from Sigma or Fisher Scientific.

Cell Culture and Treatment-- 3T3-L1 mouse fibroblasts were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. U937 leukemia cells were grown in RPMI 1640 medium supplemented with glutamine and 10% fetal calf serum. Exponentially growing cells were irradiated in a 137Cs gamma  irradiator (MARK I; J. L. Shepherd & Associates, San Fernando, CA) at dose rates of 352 Gy/min (for 100 Gy dose), 116 Gy/min (for 5 Gy dose), or 39.8 Gy/min (for 1 Gy dose). Control cells were treated exactly without irradiation. The DNA-damaging drugs AraC and cisplatin were added to the culture medium for the indicated times at a concentration of 50 µM. UV irradiation was carried out in a UV cross-linker (FB-UVXL-1000; Fisher); the culture medium was removed during irradiation. Control cells were treated exactly the same without irradiation. Cells were incubated for the indicated times, harvested, frozen in liquid nitrogen, and stored at -70 °C. When indicated, the cells were preincubated for 15 min with 100 µM genistein or 200 nM wortmannin (stock solutions in Me2SO) before treatment. Control cells were mock-treated with Me2SO.

Preparation of Total Extracts-- Cells were thawed in 0.5 ml of freshly prepared lysis buffer (50 mM Tris/HCl, pH 7.5, 5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 10 mM beta -mercaptoethanol, phosphatase inhibitors (50 mM NaF, 5 mM Na4P2O7, 2 mM Na3VO4, 10 nM okadaic acid) and protease inhibitors (40 µg/ml leupeptin, 40 µg/ml pepstatin, 40 µg/ml aprotinin, 0.5 mM phenylmethylsulfonyl fluoride)) plus 1% Nonidet P-40. After 10 min on ice, the lysate was centrifuged at 16,000 × g for 10 min at 4 °C, and the supernatant was collected. More than 95% of the gamma -PAK was extracted as determined by Western blotting.

Assay of gamma -PAK and alpha -PAK Activity After Immunoprecipitation-- gamma -PAK activity was assayed using histone 4 as substrate, after immunoprecipitation of the protein kinase with anti-gamma -PAK N19 antibody. alpha -PAK activity was measured with myelin basic protein as substrate after immunoprecipitation with anti-alpha -PAK N20 antibody. The radioactivity incorporated into the protein substrates was quantified using a PhosphorImager system.

JNK Activity Assay-- JNK activity was determined after precipitation of the protein kinase with glutathione S-transferase-c-Jun bound to glutathione-Sepharose beads prepared as described (19).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

To examine whether gamma -PAK activity was affected by IR, exponentially growing 3T3-L1 mouse fibroblasts and U937 human leukemia cells were exposed to 5 and 100 Gy of gamma -radiation using a 137Cs source. After irradiation, the cells were incubated for 120 min in a CO2 incubator, and lysed in buffer containing 1% Nonidet P-40. gamma -PAK activity was determined following immunoprecipitation of the protein kinase from cell extracts with histone 4 as substrate. Fig. 1A shows that 120 min after irradiation, gamma -PAK activity in 3T3-L1 cells was increased about 2-fold at doses of 5 and 100 Gy. In U937 cells, a dose of 100 Gy induced a 4-5-fold increase in gamma -PAK activity, whereas 5 Gy had no observable effect. As U937 cells undergo rapid apoptosis in response to IR, 3T3-L1 cells were chosen as a model for this study.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 1.   Activation of gamma -PAK by IR. 3T3-L1 and U937 cells were irradiated with a 137Cs gamma  source, and incubated in a CO2 incubator for the indicated times. gamma -PAK activity was measured after immunoprecipitation using histone 4 as substrate. A, histone 4 phosphorylated by gamma -PAK immunoprecipitated from control (C) and irradiated cells (Gy, 100 Gy) at 120 min post-irradiation. The values shown are the average ± S.E. of two different experiments expressed as percentage of control. B, gamma -PAK activity in 3T3-L1 cells at zero time (control) and at 30 and 120 min post-irradiation. The average value from three different experiments ± S.E. is shown. C, left panel, gamma -PAK immunoprecipitated from control (C) and irradiated 3T3-L1 cells (Gy, Gy) was used to phosphorylate histone 4 (upper panel). Similar immunoprecipitates were used for gamma -PAK quantification by Western blotting using anti-gamma -PAK N19 antibody (lower panel). C, right panel, Western blots of equal amounts of total protein from control (C) and irradiated 3T3-L1 cells (Gy, Gy) using Santa Cruz N19 antibody (N19) and antibody to active phosphorylated gamma -PAK (RR-1), as described (7).

The observed increase in gamma -PAK activity in response to IR was both dose- and time-dependent (Fig. 1B) with significant stimulation of activity observed at 30 min with doses of 1, 5, and 100 Gy, suggesting a physiologically modulated response. Maximum stimulation was observed 120 min after irradiation, as longer incubation times after irradiation did not result in further increase of gamma -PAK activity (data not shown).

When immunoprecipitates of gamma -PAK were analyzed by Western blotting, the same amount of gamma -PAK was detected in control and irradiated cells (Fig. 1C, left panel), indicating a stimulation of gamma -PAK activity in irradiated cells. This was supported further by the use of an anti-gamma -PAK antibody (RR-1), which reacted preferentially with the regulatory domain (6) of highly autophosphorylated active gamma -PAK.3 Although in response to IR no changes in total gamma -PAK protein were detected with the N19 antibody (which recognizes both active and inactive gamma -PAK), a higher level of gamma -PAK immunoreactivity was observed with the RR-1 antibody in irradiated cells as compared with control cells (Fig. 1C, right panel). This indicated that IR stimulated gamma -PAK autophosphorylation and activation.

Doses of 1 and 5 Gy of IR resulted in a temporal slowing of the growth of 3T3-L1 cells; for doses of 20 and 100 Gy, the cells stopped dividing and accumulated in the G2/M phase of the cell cycle. None of the doses of IR used in the experiments induced significant apoptosis in 3T3-L1 cells, even 48-h post-irradiation. Accordingly, no gamma -PAK activation by caspase cleavage was observed by Western blot analysis using antibodies against either the C or the N terminus of gamma -PAK (data not shown).

Although the primary cellular effect of IR is the induction of double strand DNA breaks, it also causes other changes (16). To examine if DNA damage was the trigger for gamma -PAK activation in response to IR, 3T3-L1 cells were incubated with two different DNA-damaging drugs or irradiated with increasing doses of UV, and gamma -PAK activity was determined with histone 4 as substrate after immunoprecipitation. Cisplatin, which produces interstrand cross-links in the DNA (20), was a potent activator of gamma -PAK, with a 2.5- and 5-fold stimulation of activity after incubation for 30 and 120 min, respectively (Fig. 2). The antimetabolite AraC, which is incorporated into the DNA and produces termination of DNA synthesis (21), activated gamma -PAK around 2.5-fold at both 30 and 120 min of incubation. UV, which induces mainly pyrimidine dimers in the DNA (18), activated gamma -PAK up to 3-fold 120 min after irradiation at 80 J/m2, whereas 10 J/m2 had no effect on the protein kinase activity (Fig. 2). Neither DNA-damaging drugs nor UV resulted in cleavage of gamma -PAK by caspase, as determined by Western blotting (data not shown). Thus, different types of DNA damage result in activation of gamma -PAK, supporting the idea that DNA damage is the trigger of gamma -PAK activation in response to IR.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 2.   Effects of UV radiation and the DNA-damaging drugs cisplatin and AraC on the activity of gamma -PAK. 3T3-L1 cells were treated as described and gamma -PAK activity was measured after immunoprecipitation using histone 4 as substrate. Right, histone 4 phosphorylated by gamma -PAK immunoprecipitated from nontreated control cells (C), cells incubated with 50 µM cisplatin or AraC for 120 min (CisP, AraC), and cells irradiated with the indicated doses of UV and incubated for 120 min (UV). Left, gamma -PAK activity from control cells (0 min), cells incubated with 50 µM cisplatinum (CisP) or Ara C (AraC) for 30 or 120 min. gamma -PAK activity from control cells (0 min), and cells irradiated with the indicated doses of UV at 30 or 120 min. The average value ± S.E. of three independent experiments is shown.

To study further the physiological mechanisms of gamma -PAK activation by DNA damage, 3T3-L1 cells were preincubated with or without the tyrosine kinase inhibitor genistein or the PI3-kinase inhibitor wortmannin before irradiation; DNA-damaging drugs were present in the culture medium throughout the experiments (Fig. 3). Short incubation times were used to avoid a direct effect of wortmannin or genistein on gamma -PAK activity. A significant inhibition of gamma -PAK activation by IR (5 Gy) was observed when genistein or wortmannin were present (60 and 90%, respectively). Genistein and wortmannin also abolished activation of gamma -PAK by AraC (65 and 100%, respectively). The PI3-kinase inhibitor Ly 294002 also inhibited gamma -PAK activation by IR or AraC (data not shown), further supporting the involvement of PI3-kinase activity in the activation of gamma -PAK. Cisplatin activation of gamma -PAK was not affected by wortmannin and only slightly affected by genistein, whereas neither compound inhibited activation of gamma -PAK by UV.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of genistein and wortmannin on activation of gamma -PAK by IR and other DNA-damaging agents. gamma -PAK activity was determined with histone 4 as substrate after immunoprecipitation from 3T3-L1 cells. G, cells preincubated for 15 min with 100 µM genistein; W, cells preincubated for 15 min with 200 nM wortmannin. IR, 5 Gy of IR, 30 min of incubation after irradiation; CisP, AraC, 50 µM cisplatin or AraC for 30 min; UV, 80 J/m2 of UV, 1 h of incubation after irradiation. The average value for three independent experiments ± S.E. is shown. Significant differences between control cells and cells treated with genistein or wortmannin are marked as follows: *, p < 0.05; **, p < 0.1.

The fact that both genistein and wortmannin interfered with the activation of gamma -PAK by IR and AraC indicated that tyrosine kinase and PI3-kinase activity are essential upstream activators of gamma -PAK in response to these DNA-damaging treatments. In contrast, UV and cisplatin activation of gamma -PAK is independent of tyrosine kinase and PI3-kinase activity. This suggests the involvement of more than one pathway in the control of gamma -PAK activity in response to different types of DNA damage.

To determine whether gamma -PAK activation in response to DNA damage was a general feature of other members of the PAK family, alpha -PAK activity was assayed after immunoprecipitation from control and treated 3T3-L1 cells (Fig. 4A). No activation of alpha -PAK in response to IR or AraC was observed, indicating that alpha -PAK and gamma -PAK were differentially regulated. In contrast, alpha -PAK was activated 2.4- and 1.8-fold, respectively, by cisplatin and UV.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of IR on alpha -PAK and JNK activity. A, alpha -PAK activity measured with myelin basic protein as substrate following immunoprecipitation from 3T3-L1 cells extracts. Right, myelin basic protein phosphorylated by alpha -PAK immunoprecipitated from nontreated control cells (C), cells irradiated with 1 or 5 Gy and incubated 120 min after irradiation (IR), cells incubated with 50 µM cisplatin or AraC for 120 min (CisP, AraC), and cells irradiated with the indicated doses of UV and incubated for 120 min after irradiation (UV). Left, Average ± S.E. of three independent experiments. B, JNK activity measured after precipitation with c-Jun from extracts of 3T3-L1 cells. C, nontreated control cells, IR, cells irradiated with the indicated doses of IR, and incubated for 120 min after irradiation; CisP, AraC, cells treated with 50 µM cisplatin or AraC for 120 min; UV, cells irradiated with 80 J/m2 of UV, and incubated for 120 min after irradiation. The average ± S.E. of two independent experiments is shown.

It has been suggested that the stress-activated protein kinase JNK acts downstream of PAK (5, 22, 23), even though this has been questioned (24-26). Thus, we examined whether JNK was activated in response to the different DNA-damaging treatments that were able to activate gamma -PAK. No activation of JNK was observed in 3T3-L1 cells 120 min after irradiation with doses of 1, 5, or 100 Gy of IR, as determined by phosphorylation of c-Jun (Fig. 4B). Longer incubation times after irradiation (up to 6 h) did not induce JNK activation (data not shown). The DNA-damaging drugs cisplatin and AraC also failed to activate JNK significantly; in contrast, JNK was activated by UV (80 J/m2) in 3T3-L1 cells (Fig. 4B). The data is consistent with results previously reported for NIH 3T3 cells, wherein IR doses up to 100 Gy failed to activate JNK, although inducing c-Abl activation or p53 accumulation (27). It is interesting to note that in 3T3-L1 cells, stress-inducing agents like the drugs anisomycin and arsenite are able to activate JNK without any observable effect on gamma -PAK activity (data not shown).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

gamma -PAK is activated up to 5-fold during the early response to IR in 3T3-L1 fibroblasts and U937 leukemia cells. This activation is time- and dose-dependent, and correlates with an increase in the amount of phosphorylated gamma -PAK present in the cells. Caspase cleavage is not involved in the observed activation of gamma -PAK, because no fragments of gamma -PAK are detected by Western blotting. gamma -PAK activation by IR is dependent on tyrosine kinase and PI3-kinase activity, as shown by use of the inhibitors genistein and wortmannin. A direct involvement of PI3-kinase (perhaps through activation of Cdc42) in the response to IR cannot entirely be ruled out, but wortmannin could also act through inhibition of the PI3-kinase-related enzymes DNA-dependent protein kinase or ATM. These protein kinases are known to have a central role in the early response to agents that induce DNA damage, such as IR (18). Other candidates for upstream activators of gamma -PAK are the tyrosine kinases c-Abl and Lyn, which have been shown to be activated in response to IR (28, 29). Because gamma -PAK activation in vitro requires autophosphorylation of both the regulatory and catalytic domains of the enzyme (30-32), the data suggest that autophosphorylation and phosphorylation by other kinases may be involved in activation in vivo.

gamma -PAK is activated in response to different types of DNA damage such as double strand breaks (IR), interstrand links (cisplatin), chain termination (AraC), and pyrimidine dimer formation (UV). Like IR, AraC activation of gamma -PAK is dependent on PI3-kinase and tyrosine kinase activities; in contrast, activation by cisplatin and UV is not. This suggests that gamma -PAK activity can be regulated by at least two different signaling pathways; one activated by IR and AraC, which requires PI3-kinase and tyrosine kinase activity, and another pathway activated by cisplatin and UV, which is not significantly affected by wortmannin and genistein. The data are consistent with the present knowledge of the response to DNA damage in mammalian cells, where IR and UV are known to activate different signaling pathways; the response to IR is dependent on the PI3-kinase-related enzymes DNA-dependent protein kinase and ATM, whereas the pathway activated by UV is not dependent on PI3-kinase-related enzymes (18). Note that IR and AraC also activate the tyrosine kinase c-Abl, which is not activated by UV (27, 28, 33), and cisplatin activates the tyrosine kinase Abl (28), but not DNA-dependent protein kinase (34).

Because all the studied DNA-damaging treatments stimulate gamma -PAK activity, gamma -PAK activation may be a common event in the cellular response to DNA damage. In eukaryotic cells, all types of DNA damage result in delayed progression through the cell cycle, with the G2/M transition checkpoint playing a major role in preventing cell division (15, 17, 18). Both gamma -PAK and X-PAK (a gamma -PAK Xenopus homologue) inhibit G2/M transition and mitotic progression in frog oocytes and embryos (7, 35, 36). We propose that gamma -PAK activation in response to IR and other DNA-damaging treatments is related to the cytostatic properties of the kinase and is part of the common cytostatic response activated by different types of DNA damage.

Currently gamma -PAK is the only mammalian PAK that, like the yeast PAK homologue Ste20, has been related to cell cycle arrest (7, 37). alpha -PAK is not activated by IR or treatment with AraC, but it is activated by UV and cisplatin. Thus, the two different members of the PAK family can be activated by specific DNA-damaging agents, but activation of alpha -PAK is not a general response to DNA damage, as is gamma -PAK activation. In contrast to gamma -PAK, JNK is activated primarily by UV.

This is the first time that members of the Ste20/PAK family of protein kinases have been shown to be involved in the cellular response to irradiation or treatment with DNA-damaging drugs. It is suggested that gamma -PAK activation by IR and DNA damage is important in the cytostatic response elicited by these agents, as gamma -PAK has been shown previously to induce cytostasis (7, 38). Additional studies are underway in our laboratory to determine the requirements for activation of gamma -PAK in response to IR and to define the role of the protein kinase in the early response to DNA damage.

    ACKNOWLEDGEMENTS

We thank Dr. Gayle E. Woloshack, Argonne National Laboratory, Chicago, IL, for introducing us to ionizing radiation experimentation, and Dr. Andrew J. Grosovsky, University of California, Riverside, CA, for the use of the 137Cs gamma -irradiator.

    FOOTNOTES

* This work was supported by United States Public Health Service Grant GM26738.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Biochemistry, University of California, Riverside, CA 92521. Tel.: 909-787-4239; Fax: 909-787-3590; E-mail: jolinda.traugh@ucr.edu.

2 R. D. Rooney and J. A. Traugh, unpublished results.

3 A. Gatti and J. A. Traugh, unpublished results.

    ABBREVIATIONS

The abbreviations used are: PAK, p21-activated protein kinase; IR, ionizing radiation; PI3-kinase, phosphoinositide 3-kinase; AraC, cytosine beta -D-arabinofuranoside; cisplatin, cis-platinum(II)diammine dichloride; JNK, c-Jun N-terminal kinase; Gy, gray.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Lim, L., Manser, E., Leung, T., and Hall, C. (1996) Eur. J. Biochem. 242, 171-185[Medline] [Order article via Infotrieve]
2. Sells, M. A., and Chernoff, J. (1997) Trends Cell Biol. 7, 162-167
3. Knaus, U. G., and Bokoch, G. M. (1998) Int. J. Biochem. Cell Biol. 30, 857-862[CrossRef][Medline] [Order article via Infotrieve]
4. Rudel, T., and Bokoch, G. M. (1997) Science 276, 1571-1574[Abstract/Free Full Text]
5. Lee, N., MacDonald, H., Reinhard, C., Halenbeck, R., Roulston, A., Shi, T., and Williams, L. T. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 13642-13647[Abstract/Free Full Text]
6. Walter, B. N., Huang, Z., Jakobi, R., Tuazon, P. T., Alnemri, E. S., Litwack, G., and Traugh, J. A. (1998) J. Biol. Chem. 273, 28733-28739[Abstract/Free Full Text]
7. Rooney, R. D., Tuazon, P. T., Meek, W. E., Carroll, E. J., Hagen, J. J., Gump, E. L., Monnig, C. A., Lugo, T., and Traugh, J. A. (1996) J. Biol. Chem. 271, 21498-21504[Abstract/Free Full Text]
8. Roig, J., Lytle, C., and Traugh, J. A. (1999) FASEB J. 13, 1579 (abstr.)
9. Sells, M. A., Knaus, U. G., Bagrodia, S., Ambrose, D. M., Bokoch, G. M., and Chernoff, J. (1997) Curr. Biol. 7, 202-210
10. Manser, E., Huang, H. Y., Loo, T. H., Chen, X. Q., Dong, J. M., Leung, T., and Lim, L. (1997) Mol. Cell. Biol. 17, 1129-1143[Abstract]
11. Zhao, Z. S., Manser, E., Chen, X. Q., Chong, C., Leung, T., and Lim, L. (1998) Mol. Cell. Biol. 18, 2153-2163[Abstract/Free Full Text]
12. Dharmawardhane, S., Sanders, L. C., Martin, S. S., Daniels, R. H., and Bokoch, G. M. (1997) J. Cell Biol. 138, 1265-1278[Abstract/Free Full Text]
13. Tsakiridis, T., Taha, C., Grinstein, S., and Klip, A. (1996) J. Biol. Chem. 271, 19664-19667[Abstract/Free Full Text]
14. King, A. J., Sun, H., Diaz, B., Barnard, D., Miao, W., Bagrodia, S., and Marshall, M. S. (1998) Nature 396, 180-183[CrossRef][Medline] [Order article via Infotrieve]
15. Bernhard, E. J., Maity, A., Muschel, R. J., and McKenna, W. G. (1995) Radiat. Environ. Biophys. 34, 79-83[CrossRef][Medline] [Order article via Infotrieve]
16. Woloschak, G. E. (1997) in Stress-inducible Processes in Higher Eukaryotic Cells (Koval, T. M., ed) , pp. 185-219, Plenum Press, New York
17. Rhind, N., and Russell, P. (1998) Curr. Opin. Cell Biol. 10, 749-758[CrossRef][Medline] [Order article via Infotrieve]
18. Wang, J. Y. (1998) Curr. Opin. Cell Biol. 10, 240-247[CrossRef][Medline] [Order article via Infotrieve]
19. Dérijard, B., Hibi, M., Wu, I. H., Barrett, T., Su, B., Deng, T., Karin, M., and Davis, R. J. (1994) Cell 76, 1025-1037[CrossRef][Medline] [Order article via Infotrieve]
20. Sherman, S. E., and Lippard, S. J. (1987) J. Chem. Rev. 87, 1153-1181
21. Kufe, D. W., Munroe, D., Herrick, D., Egan, E., and Spriggs, D. (1984) Mol. Pharmacol. 26, 128-134[Abstract]
22. Bagrodia, S., Dérijard, B., Davis, R. J., and Cerione, R. A. (1995) J. Biol. Chem. 270, 27995-27998[Abstract/Free Full Text]
23. Polverino, A., Frost, J., Yang, P., Hutchison, M., Neiman, A. M., Cobb, M. H., and Marcus, S. (1995) J. Biol. Chem. 270, 26067-26070[Abstract/Free Full Text]
24. Teramoto, H., Coso, O. A., Miyata, H., Igishi, T., Miki, T., and Gutkind, J. S. (1996) J. Biol. Chem. 271, 27225-27228[Abstract/Free Full Text]
25. Minden, A., and Karin, M. (1997) Biochim. Biophys. Acta 1333, F85-F104[Medline] [Order article via Infotrieve]
26. Zhou, K., Wang, Y., Gorski, J. L., Nomura, N., Collard, J., and Bokoch, G. M. (1998) J. Biol. Chem. 273, 16782-16786[Abstract/Free Full Text]
27. Liu, Z. G., Baskaran, R., Lea-Chou, E. T., Wood, L. D., Chen, Y., Karin, M., and Wang, J. Y. (1996) Nature 384, 273-276[CrossRef][Medline] [Order article via Infotrieve]
28. Kharbanda, S., Ren, R., Pandey, P., Shafman, T. D., Feller, S. M., Weichselbaum, R. R., and Kufe, D. W. (1995) Nature 376, 785-788[CrossRef][Medline] [Order article via Infotrieve]
29. Kharbanda, S., Yuan, Z. M., Rubin, E., Weichselbaum, R., and Kufe, D. (1994) J. Biol. Chem. 269, 20739-20743[Abstract/Free Full Text]
30. Gatti, A., Huang, Z., Tuazon, P. T., and Traugh, J. A. (1999) J. Biol. Chem. 274, 8022-8028[Abstract/Free Full Text]
31. Tuazon, P. T., Chinwah, M., and Traugh, J. A. (1998) Biochemistry 37, 17024-17029[CrossRef][Medline] [Order article via Infotrieve]
32. Tuazon, P. T., Roig, J., Gatti, A., and Traugh, J. A. (1999) FASEB J. 13, A1490
33. Kharbanda, S., Pandey, P., Ren, R., Mayer, B., Zon, L., and Kufe, D. (1995) J. Biol. Chem. 270, 30278-30281[Abstract/Free Full Text]
34. Turchi, J. J., Patrick, S. M., and Henkels, K. M. (1997) Biochemistry 36, 7586-7593[CrossRef][Medline] [Order article via Infotrieve]
35. Faure, S., Vigneron, S., Dorée, M., and Morin, N. (1997) EMBO J. 16, 5550-5561[CrossRef][Medline] [Order article via Infotrieve]
36. Faure, S., Vigneron, S., Galas, S., Brassac, T., Delsert, C., and Morin, N. (1999) J. Biol. Chem. 274, 3573-3579[Abstract/Free Full Text]
37. Herskowitz, I. (1995) Cell 80, 187-197[CrossRef][Medline] [Order article via Infotrieve]
38. Huang, Z., and Traugh, J. A. (1999) FASEB J. 13, 1578 (abstr.)


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
S. J. Coniglio, S. Zavarella, and M. H. Symons
Pak1 and Pak2 Mediate Tumor Cell Invasion through Distinct Signaling Mechanisms
Mol. Cell. Biol., June 15, 2008; 28(12): 4162 - 4172.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z. Derdak, N. M. Mark, G. Beldi, S. C. Robson, J. R. Wands, and G. Baffy
The Mitochondrial Uncoupling Protein-2 Promotes Chemoresistance in Cancer Cells
Cancer Res., April 15, 2008; 68(8): 2813 - 2819.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. Escriva, S. Peiro, N. Herranz, P. Villagrasa, N. Dave, B. Montserrat-Sentis, S. A. Murray, C. Franci, T. Gridley, I. Virtanen, et al.
Repression of PTEN Phosphatase by Snail1 Transcriptional Factor during Gamma Radiation-Induced Apoptosis
Mol. Cell. Biol., March 1, 2008; 28(5): 1528 - 1540.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J.-H. Jung and J. A. Traugh
Regulation of the Interaction of Pak2 with Cdc42 via Autophosphorylation of Serine 141
J. Biol. Chem., December 2, 2005; 280(48): 40025 - 40031.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. C. Orton, J. Ling, A. J. Waskiewicz, J. A. Cooper, W. C. Merrick, N. L. Korneeva, R. E. Rhoads, N. Sonenberg, and J. A. Traugh
Phosphorylation of Mnk1 by Caspase-activated Pak2/{gamma}-PAK Inhibits Phosphorylation and Interaction of eIF4G with Mnk
J. Biol. Chem., September 10, 2004; 279(37): 38649 - 38657.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S. M. S. Miah, K. Sada, P. T. Tuazon, J. Ling, K. Maeno, S. Kyo, X. Qu, Y. Tohyama, J. A. Traugh, and H. Yamamura
Activation of Syk Protein Tyrosine Kinase in Response to Osmotic Stress Requires Interaction with p21-Activated Protein Kinase Pak2/{gamma}-PAK
Mol. Cell. Biol., January 1, 2004; 24(1): 71 - 83.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Kim, P. Yang, P. Catanuto, F. Verde, H. Lai, H. Du, F. Chang, and S. Marcus
The Kelch Repeat Protein, Tea1, Is a Potential Substrate Target of the p21-activated Kinase, Shk1, in the Fission Yeast, Schizosaccharomyces pombe
J. Biol. Chem., August 8, 2003; 278(32): 30074 - 30082.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Z. Huang, J. Ling, and J. A. Traugh
Localization of p21-activated Protein Kinase gamma -PAK/Pak2 in the Endoplasmic Reticulum Is Required for Induction of Cytostasis
J. Biol. Chem., April 4, 2003; 278(15): 13101 - 13109.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. D. Gallagher, S. Xu, C. Moomaw, C. A. Slaughter, and M. H. Cobb
Binding of JNK/SAPK to MEKK1 Is Regulated by Phosphorylation
J. Biol. Chem., November 22, 2002; 277(48): 45785 - 45792.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Roig, P. T. Tuazon, P. A. Zipfel, A. M. Pendergast, and J. A. Traugh
Functional interaction between c-Abl and the p21-activated protein kinase gamma -PAK
PNAS, December 19, 2000; 97(26): 14346 - 14351.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Roig, Z. Huang, C. Lytle, and J. A. Traugh
p21-activated Protein Kinase gamma -PAK Is Translocated and Activated in Response to Hyperosmolarity. IMPLICATION OF Cdc42 AND PHOSPHOINOSITIDE 3-KINASE IN A TWO-STEP MECHANISM FOR gamma -PAK ACTIVATION
J. Biol. Chem., May 26, 2000; 275(22): 16933 - 16940.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Jakobi, E. Moertl, and M. A. Koeppel
p21-activated Protein Kinase gamma -PAK Suppresses Programmed Cell Death of BALB3T3 Fibroblasts
J. Biol. Chem., May 11, 2001; 276(20): 16624 - 16634.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. K. Reeder, I. G. Serebriiskii, E. A. Golemis, and J. Chernoff
Analysis of Small GTPase Signaling Pathways Using p21-activated Kinase Mutants That Selectively Couple to Cdc42
J. Biol. Chem., October 26, 2001; 276(44): 40606 - 40613.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roig, J.
Right arrow Articles by Traugh, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roig, J.
Right arrow Articles by Traugh, J. A.